Inclusion Criteria:  Children 6-23 months of age at enrollment, Acceptance of weekly home visits for growth surveillance, Planned residency within the study area for the duration of the study period (52 weeks), Signed informed consent from a parent or legal caregiver.  Exclusion Criteria:  Weight-for-height z-score (WHZ) <-3SD with respect to World Health Organization 2006 standards; Presence of bipedal edema; Severe illness warranting hospital referral; Congenital abnormalities potentially interfering with growth; Chronic medical condition (e.g., malignancy) requiring frequent medical attention; Known human immunodeficiency virus (HIV) infection of index child or child's mother; Severe anemia (hemoglobin <70 g/L; based on testing at enrollment); Currently consuming MNP supplements; Current participation in any other clinical trial.  Criteria for discontinuation:  A subject can be discontinued from the study for the following reasons:  Withdraws from the study (this can happen anytime as participation is voluntary and there are no further obligations). At the discretion of the principal investigator, if the participant is not compliant to the requirements of the protocol. Discontinued subjects will not be replaced. If, for any reason, a subject is discontinued from the study before the end of the evaluations, the safety procedures planned (AEs monitoring) will be conducted. Data obtained prior to subject's withdrawal will be included in analysis. Data of withdrawn patients are fully anonymized once analysis is completed.